Navigation Links
K-V Pharmaceutical Company to Host Investor Conference Call on May 5, 2010
Date:5/3/2010

overnmental Inquiries" of the Notes to the Consolidated Financial Statements in the Form 10-Q;
  • the possibility that the pending investigation by the Office of Inspector General of the Department of Health and Human Services into potential false claims under Title 42 of the U.S. Code as more fully described in  Note 18 — "Commitments and Contingencies — Litigation and Governmental Inquiries" of the Notes to the Consolidated Financial Statements in the Form 10-Q could result in significant civil fines or penalties, including exclusion from participation in federal healthcare programs such as Medicare and Medicaid;
  • delays in returning, or failure to return, certain or many of the Company's approved products to market, including loss of market share as a result of the suspension of shipments, and related costs;
  • the ability to sell or license certain assets, and the terms of such transactions;
  • the possibility that default on one type or class of the Company's indebtedness could result in cross default under, and the acceleration of, its other indebtedness; and
  • The risks detailed from time to time in the Company's filings with the SEC.

    • This discussion is not exhaustive, but is designed to highlight important factors that may impact the Company's  forward-looking statements.

    Because the factors referred to above, as well as the statements included elsewhere in this press release, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by the Company or on the Company's behalf, you should not place undue reliance on any forward-looking statements. All forward-looking statements attributable to the Company are expressly qualified in their entirety by the cautionary statements in this "Cautionary Note Regarding Forward-
    '/>"/>

    SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies
    2. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
    3. Althea Technologies Acquires Altus Pharmaceuticals(R) Assets and IP Portfolio, Establishing Technology Platform for Protein Formulations.
    4. Addex Pharmaceuticals to Present at BIO Business Forum During the Chicago BIO Convention, May 3rd - 6th, 2010
    5. Savient Pharmaceuticals To Hold First Quarter 2010 Results
    6. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
    7. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
    8. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
    9. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
    10. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
    11. Jazz Pharmaceuticals to Announce First Quarter 2010 Financial Results on May 5, 2010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
    (Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
    (Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... ), a specialty pharmaceutical company focused on ... for the treatment of acute and breakthrough ... in a placebo-controlled Phase 3 study of ... analgesia) System (NanoTab System), the primary efficacy ...
    Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
    ... RA Signs and Symptoms Compared to Placebo, ... (Nasdaq: TRBN ) today announced preliminary ... double-blind, placebo-controlled, multicenter,clinical trial of its TRU-015 ... indicated that Trubion,s TRU-015 product candidate, at,well-tolerated ...
    ... Calif., Sept. 10 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... antibodies for the treatment of cancer and,hepatitis C ... submitted a,clinical protocol with the Drug Controller General ... safety and efficacy trial of bavituximab in combination,with ...
    Cached Medicine Technology:Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 2Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 3Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 4Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 5Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 2Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 3Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 4
    (Date:5/20/2013)... The India Network Foundation, a ... insurance, announces a new pre-existing condition coverage plan: ... the years, India Network members have requested a ... maximums, and duration. The Platinum Comprehensive Plan is ... the valuable coverage and benefits of a PPO ...
    (Date:5/20/2013)... Heritage Woods of Gurnee , ... Illinois, is hosting Breakfast and Bingo at 8:30 a.m. ... located at 3775 Grand Ave. in Gurnee, Illinois, serves ... who need some help to maintain their independence. , ... of bingo," says Tammy Temaner-Rosas, Director of Marketing for ...
    (Date:5/20/2013)... May 21, 2013 For the ... the Best of Frederick Award in the Professional ... Association (USCA). , The USCA "Best of Local ... the country. Each year, the USCA identifies companies ... in their local community and business category. These ...
    (Date:5/20/2013)... May 20, 2013 Recent environmental ... of using green and sustainable inputs in packaging ... implemented regulations to promote the use of sustainable ... and Labelling Services industry . “Tax subsidies and ... says IBISWorld industry analyst Deonta Smith. “For example, ...
    (Date:5/20/2013)... Dr. Robert Mokbel is one of the ... the Laser Assisted New Attachment Procedure, a laser ... disease. LANAP may help many Fountain Valley residents who ... the jawbone support necessary to support dental implants. , ... tartar in the mouth. Daily oral hygiene activities typically ...
    Breaking Medicine News(10 mins):Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 3Health News:Heritage Woods of Gurnee Affordable Assisted Living Community to Host Breakfast and Bingo 2Health News:A2LA Receives 2013 Best of Frederick Award 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Fountain Valley, Ca Gum Disease Patients with Missing Teeth Can Now Receive Laser Gum Surgery from Dr. Robert Mokbel for Success with Dental Implants 2
    ... of Minnesota scientists anti-angiogenics are compounds that are very ... molecules which cut of the blood supply to the ... The study results appear in the Journal of the ... drugs that increases the potential for good, effective treatment ...
    ... monitoring data human welfare, spread of infectious disease and food ... to acquire the proper balance between ecological systems//. ... has used a satellite imagery to enable the study of ... effect on human health and food security. ,Doug ...
    ... of Kansas State University, Doug Goodin, makes use of ... and land cover //changes on human health and food ... sensing with other types of data, to monitor and ... scientists he recently discussed this subject at the workshop, ...
    ... to zero in (on) the modalities of a drug, capable ... Clinical trials on animal models have revealed the capacity of ... in charge of energy production., ,'Many drugs block ... Glick, who is the Werner E. Bachmann Collegiate Professor of ...
    ... NHS can be freed from its’ problems, if privatization ... are implemented. // It is amply clear that the ... worse for the deprived and under privileged sections of ... low morale among Doctors and NHS staff. Quality of ...
    ... BARACLUDE? (entecavir) for the treatment of chronic hepatitis B ... General of India. ,BARACLUDE (entecavir) is indicated ... in adults with evidence of active viral replication and ... or AST) or histologically active disease. ,BARACLUDE? ...
    Cached Medicine News:Health News:Ecological Changes affects human health, food security 2Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:Autoimmune disorders studied in detail by U-M researchers. 2Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
    Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
    Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
    Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
    ... next generation system for ... the power of automation ... laboratory. As many as ... loaded and analyzed in ...
    Medicine Products: